Table 2.
Prevalence rates of potential systemic corticosteroid-induced comorbidity.
| Comorbidity | Prevalence ratesa |
||
|---|---|---|---|
| Non-astma controls |
Mild/moderate Asthma |
Severe Asthma |
|
| % | % | % | |
| Type II diabetes | 6% | 7% | 10% |
| Obesity (BMI >30) | 23% | 35% | 42% |
| Osteopenia | 2% | 2% | 10% |
| Osteoporosis | 3% | 4% | 16% |
| Fracture | 4% | 3% | 5% |
| Dyspeptic disorders | 24% | 34% | 65% |
| Glaucoma | 3% | 3% | 4% |
| Cataract | 4% | 5% | 9% |
| Cardiovascular disease | 7% | 7% | 10% |
| Hypertension | 25% | 29% | 34% |
| Psychiatric disorders | 25% | 31% | 38% |
| Hypercholesterolaemia | 11% | 14% | 15% |
| Sleep disorder | 2% | 3% | 4% |
| Chronic kidney disease | 7% | 9% | 14% |
Sweeney J et al. Thorax 2016; 71:339–346.
a
2-year study period.